Compare GEVO & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GEVO | PRTC |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | United States | United States |
| Employees | 151 | 90 |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 468.8M | 400.2M |
| IPO Year | 2010 | N/A |
| Metric | GEVO | PRTC |
|---|---|---|
| Price | $2.00 | $17.87 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $6.42 | N/A |
| AVG Volume (30 Days) | ★ 4.4M | 3.2K |
| Earning Date | 05-12-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.82 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $711,000.00 | N/A |
| Revenue This Year | $19.44 | N/A |
| Revenue Next Year | $5.59 | N/A |
| P/E Ratio | ★ N/A | $8.09 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.00 | $14.50 |
| 52 Week High | $2.97 | $19.92 |
| Indicator | GEVO | PRTC |
|---|---|---|
| Relative Strength Index (RSI) | 41.32 | 66.42 |
| Support Level | $1.94 | $16.60 |
| Resistance Level | $2.19 | $18.12 |
| Average True Range (ATR) | 0.20 | 0.40 |
| MACD | -0.07 | 0.34 |
| Stochastic Oscillator | 10.36 | 87.31 |
Gevo Inc is a growth-oriented company that focuses on hard to decarbonize market sectors such as jet fuel, certain specialty fuels, on-road fuels, chemicals and materials, and certain products for the food chain such as protein and feeds made as co-products from its processes. It produces and sells competitively priced, renewable, drop-in products for these sectors, and generate carbon abatement value through its plant design and business systems. It owns and operates an ethanol plant with an adjacent CCS facility, Class VI carbon-storage well, and others. The group is currently developing the world's first large-scale ATJ facility to be co-located at the North Dakota site.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.